BMC Health Services Research

Table 2 Efficacy of treatments

From: Cost-effectiveness analysis of dapagliflozin for the treatment of type 2 diabetes mellitus in Spain: results of the DECLARE-TIMI 58 study

Variable	Dapagliflozin	Placebo	Distribution	Reference
∆ HbA1c (%)	-0.679	-0.151	Normal	[9]
∆ Weight (kg)	-2.415	-0.630	Normal	[9]
∆ SBP (mmHg)	-2.810	-0.409	Normal	[9]
∆ eGFR (ml/min/1.73m²)	-1.780	-2.440	Normal	[21]
Adverse events
Diabetic ketoacidosis	0.0007	0.0003	Normal	[9]
Urinary tract infection	0.0035	0.0037	Normal	[9]
Genital tract infection	0.0021	0.0003	Normal	[9]
Acute kidney failure	0.0035	0.0049	Normal	[9]
Fractures	0.0126	0.0025	Normal	[9]
Severe hypoglycemia	0.0016	0.0023	Normal	[9]
Discontinuation rate	0.049	0.000	Normal	[9]

eGFR estimated glomerular filtration rate, HbA1c glycated hemoglobin, SBP systolic blood pressure

Back to article page

ISSN: 1472-6963

Contact us

General enquiries: journalsubmissions@springernature.com